Recent Insider Transactions • Aug 06
CEO & Executive Director recently bought US$667k worth of stock On the 3rd of August, Ivor Elrifi bought around 667k shares on-market at roughly US$1.00 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ivor's only on-market trade for the last 12 months. Announcement • Aug 01
Tiziana Life Sciences Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab Tiziana Life Sciences Ltd. announced quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing. Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment with intranasal foralumab. The third MSA patient to complete dosing has shown up to 34% reduction in standardized uptake value (SUV) and 26% reduction in standardized uptake value ratio (SUVR) in the most affected areas relevant to MSA (basal ganglia and cerebellar white matter) in the brain. These findings are similar to the first two MSA patients, who showed up to approximately 35% reduction in standardized uptake value (SUV) and 24% reduction in standardized uptake value ratio (SUVR). PET imaging comparisons conducted before and after treatment demonstrated marked reductions in radiotracer uptake across disease-relevant brain regions. These findings suggest a reduction in neuroinflammatory activity following administration of intranasal foralumab. Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to modulate the immune system through mucosal tolerance mechanisms and reduce inflammation without the systemic toxicities associated with traditional anti-CD3 therapies. MSA is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia. There are currently no approved disease-modifying treatments for the condition. Tiziana plans to continue evaluating intranasal foralumab in additional patients to further validate these findings and better characterize the therapy’s potential to reduce neuroinflammation in MSA. Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923). Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. Announcement • Jun 15
Tiziana Life Sciences Ltd announced that it has received $0.01665 million in funding from Panetta Partners Limited Tiziana Life Sciences, Ltd. announced a private placement with Panetta Partners Ltd to issue 15,000 common shares at an issue price of $1.11 for the proceeds of $16,650 on June 15, 2026. 
